The impact of simvastatin vs. atorvastatin on cognitive function in obese hypertensives
https://doi.org/10.18705/1607-419X-2012-18-3-228-234
Abstract
Objective. To assess the influence of simvastatin vs. atorvastatin therapy on cognitive function in obese hypertensive patients. Design and methods. This open clinical trial included 40 patients (mean age 47,7 ± 5,6 years). 20 patients received simvastatin and 20 — atorvastatin. Monotherapy lasted 12 months. At baseline and 12 months later, all participants underwent neuropsychological testing and cognitive evoked potential (P300) to assess cognitive function. Results. 12-month therapy with simvastatin and atorvastatin significantly improved cognitive function (neuropsychological testing and P300) in obese hypertensives.
About the Authors
I. B. Zueva
Almazov Federal Heart, Blood, and Endocrinology Centre, St Petersburg, Russia
Russian Federation
Russian Federation
K. I. Vanaeva
Almazov Federal Heart, Blood, and Endocrinology Centre, St Petersburg, Russia
Russian Federation
Russian Federation
E. L. Sanez
Almazov Federal Heart, Blood, and Endocrinology Centre, St Petersburg, Russia
Russian Federation
Russian Federation
References
1. King D.S., Wilburn A.J., Wofford M.R., Нагге11 T.K., Lind-ley B.J., Jones D.W. Cognitive impaiiment associated with ator-vastatin and simvastatin // Pharmacotherapy. — 2003. — Vol. 23, № 12. — P. 1663-1667.
2. Muldoon M.F., Ryan C.M., Sereika S.M., Flory J.D., Manuck S.B. Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults // Am. J. Med. — 2004. — Vol. 117, № 11. — P. 823-829.
3. Shepherd J., Blauw G.J., Murphy M.B. et al. Pravastatin in elderiy individuals at risk of vascular disease (PROSPER): a randomised controlled trial // Lancet. — 2002. — Vol. 360, № 9346. — P. 1623-1630.
4. Heart Protection Study Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial // Lancet. — 2002. — Vol. 360, № 9326. — P. 7-22.
5. Yaffe K., Connor E., Lin F., Grady D. Semm lipoprotein levels, statin use, and cognitive function, in o1der women // Arch. Neurol. — 2002. — Vol. 59, № 3. — P. 378-384.
6. Li G., Higdon R., Kukull W.A. et al. Statin therapy and risk of dementia in the elderiy: a community based prospective cohort study // Neurology. — 2004. — Vol. 63, № 9. — P. 1624-1628.
7. Cramer C., Haan M.N., Galea S., Langa K.M., Kalb-fleisch J.D. Use of statin and incidence of dementia and cognitive impairment without dementia in a cohort study // Neurology. — 2008. — Vol. 71, № 5. — P. 344-350.
8. Golomb B.A. Implications of statin adverse effects in the elderly // Expert Opin. Drug Saf. — 2005. — Vol. 4, № 3. — P. 389-397.
9. Amarenco P., Tonkin A.M. Statins for stroke prevention; disappointment and hope // Circulation. — 2004. — Vol. 109, № 23, Suppl. L. — P. Ш44-Ш49.
10. Collins R., Armitage J., Parish S. et al. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high risk conditions // Lancet. — 2004. — Vol. 363, № 9411. — P. 757-767.
11. Sparks D.L., Sabbagh M.N., Connor D.J. et al. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results // Arch. Neurol. — 2005. — Vol. 62, № 5. — P. 753-757.
12. Sparks D.L., Kryscio R.J., Sabbagh M.N., Connor D.J., Sparks L.M., Liebsack C. Reduced risk of incident AD with elective statin use in a clinical trial cohort // Curr. Alzheimer Res. — 2008. — Vol. 5, № 4. — P. 416-421.
13. Brass L.M., Alberts M.J., Sparks L.; National Lipid Association Statin Safety Task Force Neurology Expert Panel. An assessment of statin safety by neurologists // Am. J. Cardiol. — 2006. — Vol. 97, № 8A. — Р 86С-88С.
14. Haag M., Hofman A., Koudstaal P.J., Stricker C., Breteler B. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study // J. Neurol. Neurosurg. Psychiatry. — 2009. — Vol. 80, № 1. — P. 13-17.
15. King D.S., Wilburn A.J., Wofford M.R. et al. Cognitive impairment associated with atorvastatin and simvastatin // Pharmacotherapy. — 2003. — Vol. 23, № 12. — Р 1663-1667.
16. Orsi A., Sherman O., Woldeselassie Z. Simvastatin-associated memory loss // Pharmacotherapy. — 2001. — Vol. 21, № 6. — P. 767-769.
17. Elias M.F., Sullivan L.M., D’Agostino R.B. et al. Framingham stroke risk profile and lowered cognitive performance // Stroke. — 2004. — Vol. 35, № 2. — Р 404-409.
18. Pavlik V.N., Hyman D.J., Doody R. Cardiovascular risk factors and cognitive function in adults 30-59 years of age (NHANES III) // Neuroepidemiology. — 2005. — Vol. 24, № 1-2. — Р 2-50.
19. Prencipe M., Santini M., Casini A.R. et al. Prevalence of non-dementing cognitive disturbances and their association with vascular risk factors in an elderly population // J. Neurol. — 2003. — Vol. 250, № 8. — P. 907-912.
20. Saxby B.K., Harrington F., McKeith I.G. et al. Effects of hypertension on attention, memory, and executive function in older adults // Health Psychol. — 2003. — Vol. 22, № 6. — Р. 587-591.
21. Зуева И.Б., Ванаева К.И., Санец Е.Л. и др. Взаимосвязь факторов сердечно-сосудистого риска с когнитивными функциями у пациентов среднего возраста // Артериальная гипертензия. — 2011. — Т. 17, № 5. — С. 432-440.
22. Messerli F.H., Sichrovsky T. When premature is not premature — the ASCOT study // Eur. Heart J. — 2005. — Vol. 26, № 18. — Р. 1822-1823.
23. Sniderman A., Solhpour A. Targeting targets for LDL-lowering therapy: lessons from the Collaborative Atorvastatin Diabetes Study (CARDS) // Clin. Chem. — 2009. — Vol. 55, № 3. — Р. 391-393.
24. Jick H., Zornberg G.L., Jick S.S., Seshadri S., Drach-man D.A. Statins and the risk of dementia // Lancet. — 2000. — Vol. 356, № 9242. — Р. 1627-1631.
25. Pedersen T.R., Kjekshus J., Berg K. et al. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994 // Atheroscler. Suppl. — 2004. — Vol. 5, № 3. — Р. 81-87.
26. Feely J., McGettigan P., Kelly A. Growth in use of statins after trials is not targeted to most appropriate patients // Clin. Pharmacol. Ther. — 2000. — Vol. 67, № 4. — Р. 438-441.
27. Harder S., Mohr O., Klepzig H. Lipid-lowering treatment in coronary artery disease: a survey in an ambulatory outpatient clinic // Int. J. Clin. Pharmacol. Ther. — 2001. — Vol. 39, № 12. — Р. 534-538.
28. Austin P.C., Mamdani M.M. Impact of the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22/Reversal of Atherosclerosis with Aggressive Lipid Lowering trials on trends in intensive versus moderate statin therapy in Ontario, Canada // Circulation. — 2005. — Vol. 112, № 9. — Р. 1296-1300.
29. Howard V.J., Cushman M., Pulley L. et al. The reasons for geographic and racial differences in stroke study: objectives and design // Neuroepidemiology. — 2005. — Vol. 25, № 3. — Р. 135-143.
30. Peters J.T., Garwood C.L., Lepczyk M. Behavioral changes with paranoia in an elderly woman taking atorvastatin // Am. J. Geriatr. Pharmacother. — 2008. — Vol. 6, № 1. — Р. 28-32.
31. Дамулин И.В. Болезнь Альцгеймера и сосудистая деменция / Под ред. Н.Н. Яхно. — М., 2002. — 85 c
32. Erkinjuntti T., Roman G., Gauthier S. et al. Emerging therapies for vascular dementia and vascular cognitive impairment // Stroke. — 2004. — Vol. 35, № 4. — P. 1010-1017.
33. Engelhart M.J., Geerlings M.I., Meijer J. et al. Inflammatory proteins in plasma and the risk of dementia: the Rotterdam study // Arch. Neurol. — 2004. — Vol. 61, № 5. — P. 668-672.
34. Schmidt R., Schmidt H., Curb J.D., Masaki K., White L.R., Launer L.J. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study // Ann. Neurol. — 2002. — Vol. 52, № 2. — P. 168-174.
35. Bernick C., Katz R., Smith N.L. et al.; Cardiovascular Health Study Collaborative Research Group. Statins and cognitive function in the elderly. The Cardiovascular Health Study // Neurology. — 2005. — Vol. 65, № 9. — P. 1388-1394.
36. Szwast S.J., Hendrie H.C., Lane K.A. et al. Association of statin use with cognitive decline in elderly African Americans // Neurology. — 2007. — Vol. 69, № 19. — Р. 1873-1880.
37. Sugiyama M., Ohashi M., Takase H., Sato K., Ueda R., Dohi Y. Effects of atorvastatin on inflammation and oxidative stress // Heart Vessels. — 2005. — Vol. 20, № 4. — P. 133-136.
38. Albert M.A., Danielson E., Rifai N., Ridker P.M., PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study // J. Am. Med. Assoc. — 2001. — Vol. 286, № 1. — P. 64-70.
39. McGuinness B., Craig D., Bullock R., Passmore P. Statins for the prevention of dementia // Cochrane Database Syst. Rev. — 2009. — № 2. — CD003160.
40. Eckert G.P., Wood W.G., Muller W.E. Statins: drugs for Alzheimer’s disease? // J. Neural. Transm. — 2005. — Vol. 112, № 8. — Р. 1057-1071.
41. Biondi E. Prescription of lipophilic statins to Alzheimer’s disease patients: some controversies to consider // Neurol. Sci. — 2011. — Vol. 32, № 2. — Р. 195-201.
Review
For citations:
Zueva I.B., Vanaeva K.I., Sanez E.L. The impact of simvastatin vs. atorvastatin on cognitive function in obese hypertensives. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2012;18(3):228-234. (In Russ.) https://doi.org/10.18705/1607-419X-2012-18-3-228-234
Views:
960
Email this article 